Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction

This randomized clinical trial investigates the long-term efficacy of mavacamten in reducing the need for septal reduction therapy in patients with obstructive hypertrophic cardiomyopathy.